Edgepark targets broader customer, prescriber base

TWINSBURG, Ohio – Innovations are expanding the number of people who can benefit from continuous glucose monitoring and a recent move by Edgepark to add the Dexcom Stelo and Eversense 365 to its portfolio allows the company to meet increased demand. 

"To manage diabetes in the most optimal way is different for each individual, so we've really been focused on that as these innovations come to market,” said Kattrina Richardson, vice president of marketing, ADSG | Edgepark, which is part of Cardinal Health. “How can we make them available so that there's choice when a prescriber might believe that one device is best, or an individual based on their specific condition?” 

Cardinal Health has been strategically focused on the diabetes market, pairing Edgepark with ADSG earlier this year. Edgepark now offers 10 different CGMs from four manufacturers, in addition to a broad range of diabetes testing supplies, insulin pumps and other supplies. 

The Dexcom Stelo, the first-ever FDA-cleared, over-the-counter glucose biosensor, is gaining traction among people with diabetes who haven’t historically qualified for a prescription-based CGM. It’s also catching the eyes of people without diabetes who are interested in understanding their metabolic health. 

“We know that blood sugar can lead to better long-term outcomes if you stay within the healthy range, so it’s almost impossible to tell if you’re within those healthy ranges unless you have something like the Stelo,” said Richardson. 

The Eversense 365, the first and only FDA-cleared one-year implantable CGM system, which is available for individuals with Type 1 or Type 2 diabetes who are 18 or older, offers a “novel type of technology that is very, very different from things that have existed in the past,” says Richardson. It could benefit users, including athletes, that have had challenges with external sensors, she says. 

“We’re starting to see that adoption grow,” she said. 

The addition of both devices to Edgepark’s product portfolio also opens the door to a “whole new set” of prescribers in the primary care space, says Richardson. The provider’s sales team is in the field working to educate those providers about these latest technologies and others across the diabetes market. 

“There’s about 9,000 endocrinologists in the U.S. versus about 250,000 PCPs, so we’re making sure that we are leveraging our sales team out in the field, having the conversations with these new prescribers that haven't historically managed diabetes so that they can create the best care pathways,” she said. “We really just try to use this as an opportunity to amplify awareness.” 

• Related: Cardinal Health ‘really keen’ on diabetes market